⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
EXEL News
Exelixis Inc
Kuehn Law Encourages Investors of EXELIXIS, Inc. to Contact Law Firm
globenewswire.com
EXEL
Correction: Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsight
globenewswire.com
JNJ
BNTX
GMAB
IMUX
INO
PDSB
AZN
GSK
MRK
BIIB
EXEL
REGN
CUE
IOBT
RAPT
PRE
EXEL Industries : Bilan semestriel du contrat de liquidité au 30.06.2026
globenewswire.com
EXEL
Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsight
globenewswire.com
JNJ
BNTX
CUE
GMAB
IMPP
INO
AZN
GSK
MRK
BMY
EXEL
REGN
PDSB
IOVA
RPTX
Generative AI Drives Revolutionary Changes in Healthcare: Key Trends and Opportunities
globenewswire.com
MSFT
INTC
NVDA
IBM
VRSN
GOOG
RXRX
EXEL
ATOM
Comprehensive Report on Renal Cancer Pipeline Insights for 2026: Over 80 Pipeline Drugs and 75+ Companies Analyzed
globenewswire.com
EXEL
CRVS
BIIB
Exelixis Provides Update on the Phase 3 STELLAR-303 Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Patients with Metastatic Colorectal Cancer
businesswire.com
EXEL
Metastatic Prostate Cancer Market Set for Robust Growth Through 2036, Driven by The Emergence of PARP Inhibitors and PSMA-targeted Radioligand Therapies | DelveInsight
globenewswire.com
NVS
TLX
PFE
EXEL
LLY
XNCR
BTE
ORIC
MRK
ABBV
BMY
AZN
AMGN
Reco Expands Executive Team and Global Footprint to Accelerate Leadership in Enterprise AI Agent Security
prnewswire.com
EXEL
Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Trial Evaluating CABOMETYX ® (cabozantinib) in Non-Functional and Functional Neuroendocrine Tumors at ASCO 2026
businesswire.com
EXEL